vs
Side-by-side financial comparison of Nano Dimension Ltd. (NNDM) and Vanda Pharmaceuticals Inc. (VNDA). Click either name above to swap in a different company.
Nano Dimension Ltd. is the larger business by last-quarter revenue ($57.8M vs $57.2M, roughly 1.0× Vanda Pharmaceuticals Inc.). Nano Dimension Ltd. runs the higher net margin — -171.1% vs -246.8%, a 75.7% gap on every dollar of revenue. Nano Dimension Ltd. produced more free cash flow last quarter ($-21.1M vs $-29.5M).
Nano Dimension Ltd. is a leading provider of additively manufactured electronics solutions and 3D printing technologies. It designs high-precision 3D printers, related materials, and software for producing printed circuit boards, microelectronics components, and multi-layer electronic devices, serving aerospace, defense, medical, automotive, and industrial electronics segments across global markets.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
NNDM vs VNDA — Head-to-Head
Income Statement — Q4 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.8M | $57.2M |
| Net Profit | $-98.8M | $-141.2M |
| Gross Margin | 43.1% | — |
| Operating Margin | -155.1% | -70.5% |
| Net Margin | -171.1% | -246.8% |
| Revenue YoY | — | 7.6% |
| Net Profit YoY | — | -2774.3% |
| EPS (diluted) | $-0.45 | $-2.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $57.2M | ||
| Q3 25 | — | $56.3M | ||
| Q2 25 | — | $52.6M | ||
| Q1 25 | — | $50.0M | ||
| Q4 24 | $57.8M | $53.2M | ||
| Q3 24 | — | $47.7M | ||
| Q2 24 | $28.4M | $50.5M | ||
| Q1 24 | — | $47.5M |
| Q4 25 | — | $-141.2M | ||
| Q3 25 | — | $-22.6M | ||
| Q2 25 | — | $-27.2M | ||
| Q1 25 | — | $-29.5M | ||
| Q4 24 | $-98.8M | $-4.9M | ||
| Q3 24 | — | $-5.3M | ||
| Q2 24 | $-79.2M | $-4.5M | ||
| Q1 24 | — | $-4.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 43.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 45.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -70.5% | ||
| Q3 25 | — | -55.6% | ||
| Q2 25 | — | -73.2% | ||
| Q1 25 | — | -82.0% | ||
| Q4 24 | -155.1% | -19.3% | ||
| Q3 24 | — | -23.1% | ||
| Q2 24 | — | -20.1% | ||
| Q1 24 | — | -19.5% |
| Q4 25 | — | -246.8% | ||
| Q3 25 | — | -40.1% | ||
| Q2 25 | — | -51.7% | ||
| Q1 25 | — | -58.9% | ||
| Q4 24 | -171.1% | -9.2% | ||
| Q3 24 | — | -11.2% | ||
| Q2 24 | -279.4% | -9.0% | ||
| Q1 24 | — | -8.7% |
| Q4 25 | — | $-2.40 | ||
| Q3 25 | — | $-0.38 | ||
| Q2 25 | — | $-0.46 | ||
| Q1 25 | — | $-0.50 | ||
| Q4 24 | $-0.45 | $-0.09 | ||
| Q3 24 | — | $-0.09 | ||
| Q2 24 | $-0.35 | $-0.08 | ||
| Q1 24 | — | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $317.2M | $84.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $860.0M | $327.2M |
| Total Assets | $902.5M | $488.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $84.9M | ||
| Q3 25 | — | $70.0M | ||
| Q2 25 | — | $81.0M | ||
| Q1 25 | — | $111.8M | ||
| Q4 24 | $317.2M | $102.3M | ||
| Q3 24 | — | $100.5M | ||
| Q2 24 | $231.8M | $103.0M | ||
| Q1 24 | — | $125.2M |
| Q4 25 | — | $327.2M | ||
| Q3 25 | — | $466.0M | ||
| Q2 25 | — | $486.3M | ||
| Q1 25 | — | $511.4M | ||
| Q4 24 | $860.0M | $538.5M | ||
| Q3 24 | — | $541.2M | ||
| Q2 24 | $870.3M | $542.5M | ||
| Q1 24 | — | $544.0M |
| Q4 25 | — | $488.9M | ||
| Q3 25 | — | $601.1M | ||
| Q2 25 | — | $624.7M | ||
| Q1 25 | — | $631.9M | ||
| Q4 24 | $902.5M | $656.2M | ||
| Q3 24 | — | $645.1M | ||
| Q2 24 | $911.0M | $651.4M | ||
| Q1 24 | — | $652.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.9M | $-29.4M |
| Free Cash FlowOCF − Capex | $-21.1M | $-29.5M |
| FCF MarginFCF / Revenue | -36.5% | -51.6% |
| Capex IntensityCapex / Revenue | 3.8% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-110.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-29.4M | ||
| Q3 25 | — | $-31.6M | ||
| Q2 25 | — | $-15.3M | ||
| Q1 25 | — | $-33.1M | ||
| Q4 24 | $-18.9M | $-1.8M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | $-30.7M | $-6.9M | ||
| Q1 24 | — | $7.6M |
| Q4 25 | — | $-29.5M | ||
| Q3 25 | — | $-31.8M | ||
| Q2 25 | — | $-15.6M | ||
| Q1 25 | — | $-33.6M | ||
| Q4 24 | $-21.1M | $-2.0M | ||
| Q3 24 | — | $-14.7M | ||
| Q2 24 | — | $-7.0M | ||
| Q1 24 | — | $7.6M |
| Q4 25 | — | -51.6% | ||
| Q3 25 | — | -56.5% | ||
| Q2 25 | — | -29.6% | ||
| Q1 25 | — | -67.1% | ||
| Q4 24 | -36.5% | -3.8% | ||
| Q3 24 | — | -30.9% | ||
| Q2 24 | — | -13.9% | ||
| Q1 24 | — | 15.9% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 0.9% | ||
| Q4 24 | 3.8% | 0.4% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NNDM
Segment breakdown not available.
VNDA
| Fanapt | $33.2M | 58% |
| Hetlioz | $16.4M | 29% |
| PONVORY | $7.6M | 13% |
